A Comparison of Calcium Acetate/magnesium Carbonate and Sevelamer-hydrochloride Effects on Fibroblast Growth Factor-23 and Bone Markers: Post Hoc Evaluation from a Controlled, Randomized Study

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2013 Jun 22

PMID 23787550

Citations 25

Authors

Adrian Covic

Jutta Passlick-Deetjen

Miroslaw Kroczak

Beatrix Buschges-Seraphin

Adrian Ghenu

Pedro Ponce

Barbara Marzell

Angel L M de Francisco

Affiliations

Soon will be listed here.

Abstract

Background: Different phosphate binders exert differing effects on bone mineral metabolism and levels of regulating hormones. The objective of this post hoc evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects of calcium acetate/magnesium carbonate (CaMg) and a calcium-free phosphate binder, sevelamer-hydrochloride (HCl), on serum levels of fibroblast growth factor-23 (FGF-23) and markers of bone turnover.

Methods: This secondary analysis of the controlled, randomized CALMAG study, comparing the effect of CaMg and sevelamer-HCl on serum phosphorus (P), aimed to investigate the parameters described above. The analysis included 204 patients who completed the initial study per protocol (CaMg, n = 105; sevelamer-HCl, n = 99).

Results: The study showed that serum levels of FGF-23 were significantly reduced with CaMg and sevelamer-HCl, with no difference between groups at Week 25 [analysis of covariance (ANCOVA); log-intact FGF-23 (iFGF-23), P = 0.1573]. FGF-23 levels strongly correlated with serum P levels at all time points in both groups. The bone turnover parameters alkaline phosphatase (AP), bone AP (BAP), procollagen type 1 amino-terminal propeptide 1 (P1NP), osteoprotegerin (OPG), beta-crosslaps (β-CTX) and tartrate-resistant acid phosphatase 5b (TRAP 5b) increased significantly in the sevelamer-HCl group; they remained almost unchanged in the CaMg group, after the initial phase of P lowering (ANCOVA, P < 0.0001 for all except OPG, P = 0.1718).

Conclusions: CaMg and sevelamer-HCl comparably lower serum levels of iFGF-23. Changes in bone parameters were dependent on characteristics of the phosphate binder; in contrast with sevelamer-HCl, CaMg had no influence on bone turnover markers.

Citing Articles

A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.

Zheng C, Liu J, Wang T, Hu H, Chen Y Sci Rep. 2025; 15(1):2012.

PMID: 39814766 PMC: 11736078. DOI: 10.1038/s41598-024-84942-8.

Phosphorous metabolism and manipulation in chronic kidney disease.

Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A Nephrology (Carlton). 2024; 29(12):791-800.

PMID: 39433296 PMC: 11579558. DOI: 10.1111/nep.14407.

Role and Treatment of Insulin Resistance in Patients with Chronic Kidney Disease: A Review.

Nakashima A, Kato K, Ohkido I, Yokoo T Nutrients. 2021; 13(12).

PMID: 34959901 PMC: 8707041. DOI: 10.3390/nu13124349.

Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis.

Takkavatakarn K, Wuttiputhanun T, Phannajit J, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P Int Urol Nephrol. 2021; 54(2):309-321.

PMID: 33797709 DOI: 10.1007/s11255-021-02848-0.

Hyperphosphatemia and Cardiovascular Disease.

Zhou C, Shi Z, Ouyang N, Ruan X Front Cell Dev Biol. 2021; 9:644363.

PMID: 33748139 PMC: 7970112. DOI: 10.3389/fcell.2021.644363.

References

Iwata Y, Wada T, Yokoyama H, Toyama T, Kitajima S, Okumura T . Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med. 2007; 46(8):447-52. DOI: 10.2169/internalmedicine.46.6338. View

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

Bichara M, Mercier O, Borensztein P, Paillard M . Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat. J Clin Invest. 1990; 86(2):430-43. PMC: 296745. DOI: 10.1172/JCI114729. View

Tentori F, Blayney M, Albert J, Gillespie B, Kerr P, Bommer J . Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52(3):519-30. DOI: 10.1053/j.ajkd.2008.03.020. View

DHaese P, Couttenye M, Lamberts L, Elseviers M, Goodman W, Schrooten I . Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem. 1999; 45(9):1548-56. View

Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D . Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2008; 24(5):1506-23. DOI: 10.1093/ndt/gfn613. View

Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M . Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2011; 27(2):784-90. DOI: 10.1093/ndt/gfr384. View

Jorge C, Gil C, Possante M, Silva E, Andrade R, Santos N . Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients--any advantage?. Nephron Clin Pract. 2005; 101(3):c122-7. DOI: 10.1159/000086682. View

Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S . Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005; 101(2):c94-9. DOI: 10.1159/000086347. View

10.

Couttenye M, DHaese P, Van Hoof V, Lemoniatou E, Goodman W, Verpooten G . Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996; 11(6):1065-72. View

11.

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson K . Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195(1):125-31. DOI: 10.1677/JOE-07-0267. View

12.

Nakai K, Komaba H, Fukagawa M . New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 2010; 23(6):619-25. View

13.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

14.

de Francisco A, Leidig M, Covic A, Ketteler M, Benedyk-Lorens E, Mircescu G . Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010; 25(11):3707-17. PMC: 2957591. DOI: 10.1093/ndt/gfq292. View

15.

Plantinga L, Fink N, Melamed M, Briggs W, Powe N, Jaar B . Serum phosphate levels and risk of infection in incident dialysis patients. Clin J Am Soc Nephrol. 2008; 3(5):1398-406. PMC: 2518791. DOI: 10.2215/CJN.00420108. View

16.

Ferreira A, Frazao J, Monier-Faugere M, Gil C, Galvao J, Oliveira C . Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008; 19(2):405-12. PMC: 2396748. DOI: 10.1681/ASN.2006101089. View

17.

Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B . High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24(9):2792-6. DOI: 10.1093/ndt/gfp191. View

18.

Bushinsky D, Wolbach W, Sessler N, Mogilevsky R . Physicochemical effects of acidosis on bone calcium flux and surface ion composition. J Bone Miner Res. 1993; 8(1):93-102. DOI: 10.1002/jbmr.5650080112. View

19.

Barreto D, Barreto F, Carvalho A, Cuppari L, Draibe S, Dalboni M . Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract. 2008; 110(4):c273-83. DOI: 10.1159/000170783. View

20.

Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View